JP2023541430A - リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 - Google Patents

リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 Download PDF

Info

Publication number
JP2023541430A
JP2023541430A JP2023516473A JP2023516473A JP2023541430A JP 2023541430 A JP2023541430 A JP 2023541430A JP 2023516473 A JP2023516473 A JP 2023516473A JP 2023516473 A JP2023516473 A JP 2023516473A JP 2023541430 A JP2023541430 A JP 2023541430A
Authority
JP
Japan
Prior art keywords
oxo
sulfamoyl
dimethylphenyl
dihydro
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516473A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022059691A5 (https=
JP2023541430A5 (https=
Inventor
裕之 上野
卓哉 星野
ハロルド キール
アラム オガネシアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JP2023541430A publication Critical patent/JP2023541430A/ja
Publication of JPWO2022059691A5 publication Critical patent/JPWO2022059691A5/ja
Publication of JP2023541430A5 publication Critical patent/JP2023541430A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023516473A 2020-09-15 2021-09-15 リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 Pending JP2023541430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078833P 2020-09-15 2020-09-15
US63/078,833 2020-09-15
PCT/JP2021/033854 WO2022059691A1 (en) 2020-09-15 2021-09-15 Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor

Publications (3)

Publication Number Publication Date
JP2023541430A true JP2023541430A (ja) 2023-10-02
JPWO2022059691A5 JPWO2022059691A5 (https=) 2024-08-14
JP2023541430A5 JP2023541430A5 (https=) 2024-08-14

Family

ID=80776688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516473A Pending JP2023541430A (ja) 2020-09-15 2021-09-15 リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法

Country Status (6)

Country Link
US (1) US20230338342A1 (https=)
EP (1) EP4213841A4 (https=)
JP (1) JP2023541430A (https=)
KR (1) KR20230067646A (https=)
AU (1) AU2021344091A1 (https=)
WO (1) WO2022059691A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130005678A1 (en) * 2010-03-30 2013-01-03 Clavis Pharma Asa Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
WO2019107386A1 (ja) * 2017-11-29 2019-06-06 大鵬薬品工業株式会社 抗腫瘍剤
US20200157066A1 (en) * 2016-05-31 2020-05-21 Taiho Pharmaceutical Co., Ltd. Sulfonamide Compound or Salt Thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130005678A1 (en) * 2010-03-30 2013-01-03 Clavis Pharma Asa Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
US20200157066A1 (en) * 2016-05-31 2020-05-21 Taiho Pharmaceutical Co., Ltd. Sulfonamide Compound or Salt Thereof
WO2019107386A1 (ja) * 2017-11-29 2019-06-06 大鵬薬品工業株式会社 抗腫瘍剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. 9, JPN6025034659, 2003, pages 4092 - 4100, ISSN: 0005787555 *
JAPANESE JOURNAL OF DRUG INFORMATICS, vol. 11, no. 4, JPN6025034657, 2010, pages 217 - 222, ISSN: 0005787553 *
LIST OF 28 LEUKEMIA CHEMOTHERAPY REGIMEN ADOPTED, [ONLINE], JPN6025034658, 21 August 2018 (2018-08-21), ISSN: 0005787554 *
ONCOTARGET, vol. 7, no. 39, JPN6025034660, 2016, pages 63003 - 63019, ISSN: 0005787556 *

Also Published As

Publication number Publication date
EP4213841A1 (en) 2023-07-26
WO2022059691A1 (en) 2022-03-24
US20230338342A1 (en) 2023-10-26
AU2021344091A9 (en) 2024-08-08
TW202227059A (zh) 2022-07-16
KR20230067646A (ko) 2023-05-16
EP4213841A4 (en) 2024-07-24
AU2021344091A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
CN113038953B (zh) 用于治疗癌症的包括krasg12c抑制剂和一种或多种其他药学活性药剂的组合疗法
JP7828333B2 (ja) リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法
JP2023541430A (ja) リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法
CN121487738A (zh) 诱导ras gtp水解的组合物和其用途
TW202521125A (zh) 治療ｒａｓ蛋白相關疾病或病症之方法
WO2025006697A1 (en) Treatment methods for subjects with non-small cell lung cancer having an aberration in egfr
AU2022355189B2 (en) Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator
TWI914404B (zh) 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法
RU2859365C2 (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы
RU2848459C1 (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы
US20240408100A1 (en) Treatment methods for subjects having cancer with a dysregulated mapk and/or pi3k pathway
HK40129790A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2026015825A1 (en) Use of ras inhibitor for treating pancreatic cancer
HK40055650A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK40051935A (en) Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK40055650B (zh) 用於治疗癌症的包括krasg12c抑制剂和一种或多种其他药学活性药剂的组合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251112

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20251112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260213